Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of anthracycline cardiotoxicity in breast cancer
NCT07245069Phase 2Recruiting
- Sponsor
- University Medical Centre Ljubljana
- Start
- Feb 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in anthracycline-induced cardiotoxicity, sponsored by University Medical Centre Ljubljana. Started Feb 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT07245069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07245069.